

# **EXHIBIT G**



# MiMedix

## **AGENDA**

**Meeting of the Audit Committee of the Board of Directors**

**October 24, 2018**

**9:30 am – 12:00 pm EST**

**Board Room**

***Highly Confidential – Do Not Disseminate***

*The following slide is excerpted from the original*

## Investigation and Related Fees – As of September 30, 2018

(000's Omitted)

Actuals															Forecast				Total
Supplier	Q1 2018	Apr-18	May-18	Jun-18	Q2 2018	Jul-18	Aug-18	Sep-18	Q3 2018	Oct-18	Nov-18	Dec-18	Q4 2018						
Consulting - Public Company																			
KPMG	606	802	800	448	2,050	487	1,037	935	2,439	500	400	270	1,170	6,265					
K&S	1,656	2,100	2,956	1,183	6,239	626	832	1,165	2,623	800	600	450	1,850	12,368					
Davis Polk	-	-	165	510	675	500 [C]	390 [C]	(276) [D]	615	300	200	180	680	1,970					
Simpson Thatcher	-	-	1,160	593	1,753	796	(332) [C]	34	497	200	200	135	535	2,785					
Deloitte	-	-	-	20	20	127	496	679	1,302	700	700	630	2,030	3,352					
Total	2,261	2,902	5,081	2,755	10,737	2,515	2,424	2,537	7,475	2,500	2,100	1,665	6,265	26,739					
Audit Fees [A]																			
EY	430	-	495	871	1,366	358	282	149	788	300	300	270	870	3,454					
CB	40	-	-	-	-	12	206	83	301	200	200	200	600	941					
Total	470	-	495	871	1,366	370	488	232	1,090	500	500	470	1,470	4,396					
Litigation [B]																			
Sidley Austin	246	(49)	314	841	1,105	718 [C]	1,047 [C]	1,288	3,050	750	750	450	1,950	6,351					
Quinn Emanuel	-	-	-	-	-	-	1,029 [C]	-	1,029	-	-	-	-	1,029					
Total	246	(49)	314	841	1,105	718	2,076	1,288	4,079	750	750	450	1,950	7,381					
Overall Total	2,977	2,853	5,890	4,466	13,209	3,602	4,988	4,055	12,644	3,750	3,350	2,585	9,685	38,515					

[A] Investigation / restatement related only.

[B] Only includes invoices titled "SEC Investigation" / "VA OIG" / "SDNY DOJ" / "SDFL USAO".

Does not include "Audit Committee Issues" and "SEC Disclosure Advice" totaling \$1.2m YTD 2018.

[C] Includes estimate based on prior month experience.

[D] Adjusted in Sep to exclude other matters, includes estimates.

Down \$1.5M from  
prior forecast

10

10/23/2018

Company Confidential – UNAUDITED AND SUBJECT TO  
COMPLETION OF INVESTIGATION. Do Not Disseminate

MIMedix